WallStreetZenWallStreetZen

NASDAQ: CTMX
Cytomx Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Cytomx Therapeutics revenue was $138.10M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $38.1M, up 13.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CTMX annual revenue was $138.1M, with 36.4% growth year-over-year.

CTMX past revenue growth

How has CTMX's revenue growth performed historically?

Company
36.45%
Industry
497.69%
Market
20.68%
CTMX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CTMX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CTMX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CTMX revenue history

Current Revenue
$138.1M
Current Earnings
$31.9M
Current Profit Margin
23.1%

Be the first to know when CTMX announces revenue.

CTMX Revenue History By Year

CTMX Yearly RevenueCTMX RevenueCTMX ChangeCTMX Revenue Growth
2024-12-31$138.10M$36.89M+36.45%
2023-12-31$101.21M$48.05M+90.38%
2022-12-31$53.16M$15.85M+42.48%
2021-12-31$37.31M-$31.12M-45.47%
2020-12-31$68.43M$41.53M+154.36%
2019-12-31$26.90M-$32.60M-54.79%
2018-12-31$59.50M-$12.12M-16.92%
2017-12-31$71.62M$56.58M+376.12%
2016-12-31$15.04M$7.33M+95.06%
2015-12-31$7.71M$2.64M+51.90%
2014-12-31$5.08M$4.19M+471.73%
2013-12-31$888.00kN/AN/A

1 of 1

Cytomx Therapeutics Revenue FAQ

What was CTMX's revenue last quarter?

On Invalid Date, Cytomx Therapeutics (NASDAQ: CTMX) reported Q4 2024 revenue of $38.09 million up 43.17% year over year. In the same quarter last year, Cytomx Therapeutics's revenue was $26.61 million.

What was Cytomx Therapeutics's revenue in 2024?

Cytomx Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $138.10 million, a 36.45% increase year over year.

How much does Cytomx Therapeutics make in a day?

Based on Cytomx Therapeutics annual revenue for the past five years, CTMX makes an average of $218,202.19 per day.

What was Cytomx Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Cytomx Therapeutics's revenue has grown 36.45% year over year. This is 461.25 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Cytomx Therapeutics's revenue in the past year totaled $138.10 million.

How much does Cytomx Therapeutics make in a year?

Cytomx Therapeutics's revenue by year for the past five years is:
  • Cytomx Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $138.10 million, a 36.45% increase year over year.
  • Cytomx Therapeutics's annual revenue for Dec 31, 2023 was $101.21 million, a 90.38% increase from 2022.
  • Cytomx Therapeutics's annual revenue for 2022 was $53.16 million, a 42.48% increase from 2021.
  • Cytomx Therapeutics's annual revenue for 2021 was $37.31 million, a 45.47% decrease from 2020.
  • Cytomx Therapeutics's annual revenue for 2020 was $68.43 million, a 154.36% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.